Skip to content

Baclofen in the treatment of Autism

Baclofen as adjunctive treatment of Autism: A double blind and placebo controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201701131556N95
Enrollment
40
Registered
2017-01-13
Start date
2017-01-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood autism. Childhood autism

Interventions

Intervention 1: Tablet Baclofen 0.6 mg/kg/day in three divided doses+ Tablet Risperidon 1-3.5 mg/day as intervention for 10 weeks. Intervention 2: Tablet Risperidone 1-3.5 mg/day +Capsule Placebo as c
Treatment - Drugs
Placebo
Tablet Baclofen 0.6 mg/kg/day in three divided doses+ Tablet Risperidon 1-3.5 mg/day as intervention for 10 weeks

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 12 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1-DSM 5 clinical diagnosis of autistic disorder; 2-children between the ages of 3 and 11 years; 3- presence of behavioral problems such as aggression, overactivity or repetitive behaviors (indication of treatment with risperidone). Exclusion criteria: 1- presence of any active medical problem; 2-any other psychiatric diagnosis except for Intellectual disability; 3-history of allergy to Baclofen; 4- receiving any psychotropic medications during past two weeks prior to the trial; 5-presence of hepatic disease; 6-history of seizure.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Severity of Autism. Timepoint: Baseline and weerks 5 and 10. Method of measurement: Aberrant Behavior Checklist-Community (ABC-C) Rating Scale (irritibility subscale) and Childhood autism rating scale(CARS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactProf. Shahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026